SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glaxosmithkline Pharmaceuticals informs about receipt of order

27 Nov 2024 Evaluate
Glaxosmithkline Pharmaceuticals has informed that the Company has received an Order dated 26th November 2024 for period FY 2017-18 from Madhya Pradesh GST authorities, setting aside the demand of Rs 13,32,726 in Madhya Pradesh State. The relevant details to be is disclosed is as enclosed.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

2406.25 -3.60 (-0.15%)
15-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1696.65
Dr. Reddys Lab 1218.30
Cipla 1226.65
Zydus Lifesciences 936.00
Lupin 2339.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×